Background: Mechanisms mediating resistance against the proteasome inhibition by
bortezomib (BTZ) in multiple myeloma (MM) cells are still unclear. We analyzed the …

The 26S proteasome inhibitor, bortezomib, has shown remarkable therapeutic efficacy in
multiple myeloma (MM), however, the mechanism by which this compound acts remains …

Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells,
remains incurable by current therapy. However, the proteasome inhibitor bortezomib and …

Bortezomib is an effective agent for treating multiple myeloma (MM). To investigate the
underlying mechanisms associated with acquired resistance to this agent, we established …

Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain
controversial. We report the existence of a progenitor organization in primary MM that …

Multiple myeloma (MM) is an incurable plasma cell malignancy. The 26S proteasome
inhibitor, bortezomib, selectively induces apoptosis in MM cells; however, the nature of its …

The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple
myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often …

Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM),
though a number of patients show resistance to this drug. To study the cellular basis of this …

Background Multiple myeloma (MM) is a hematologic malignancy that is characterized by
the proliferation of abnormal bone marrow plasma cells (BMPC) and overproduction of …

Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the
disease can become resistant through poorly defined mechanisms. In this issue of Cancer …